News - STRN-ALK fusion

3ms

STRN-ALK Fusion in Advanced Salivary Gland Carcinoma With Response to Anaplastic Lymphoma Kinase Inhibition: Case Report and Literature Review. (PubMed, WMJ)

Our patient experienced clinical benefit from first and second generation ALK inhibition in a chemotherapy refractory tumor. Tumor mutation profiling can identify mutations that may render tumors sensitive to targeted therapy with tyrosine kinase inhibitors.

3 months ago

Review • Journal • Metastases

ALK (Anaplastic lymphoma kinase) • STRN (Striatin)

ALK fusion • ALK translocation • STRN-ALK fusion

8ms

Clinicopathologic Features and Cytologic Correlation of ALK-Rearranged Papillary Thyroid Carcinoma: A Series of Eight Cases. (PubMed, Endocr Pathol)

The NGS testing revealed EML4::ALK fusion in three, STRN::ALK fusion in two, and ITSN2::ALK fusion in one. In conclusion, although ALK-rearranged PTCs have been associated with neutral gene expression profile from a BRAF-RAS scoring perspective, the "RAS-like" nuclear features were more commonly identified in this series, resulting in frequent indeterminate diagnosis of preoperative FNA.

8 months ago

Journal

BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4) • STRN (Striatin) • RAS (Rat Sarcoma Virus)

ALK rearrangement • ALK fusion • STRN-ALK fusion

VENTANA ALK (D5F3) CDx Assay

9ms

Reticular Myxoid Odontogenic Neoplasm with Novel STRN::ALK Fusion: Report of 2 Cases in 3-Year-Old Males. (PubMed, Head Neck Pathol)

Both patients were treated with surgical resection and reconstruction. The prognosis of patients with this entity is currently uncertain but shall become more apparent over time as more cases are identified and followed.

9 months ago

Journal

ALK (Anaplastic lymphoma kinase) • STRN (Striatin)

ALK rearrangement • ALK fusion • STRN-ALK fusion

11ms

Ciliated Muconodular Papillary Tumors of the Lung Harboring STRN::ALK Fusion: Case Report and Review of the Literature. (PubMed, Int J Surg Pathol)

Consequently, we conducted a review of relevant literature, summarizing the clinicopathological and molecular characteristics of CMPT to facilitate further research. Our insights enhance the understanding of this uncommon tumor and contribute to the expansion of its molecular alteration spectrum.

11 months ago

Review • Journal

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • STRN (Striatin)

ALK rearrangement • ALK fusion • STRN-ALK fusion • EGFR rearrangement

1year

Plasma-Based Genotyping For Monitoring Patients With Thyroid Cancer (ATA 2023)

Although the methodology is still evolving, our findings suggest that this non‐invasive approach can be incorporated into the routine management of patients with malignant thyroid neoplasm as it may help the early detection of therapeutically targetable mutations. We emphasize that liquid biopsy test can be repeated through the follow‐up to complement existing tests with low cost and convenience for the patient. We also anticipate that that this blood test may help early detection of thyroid tumors.

1 year ago

Clinical

BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TERT (Telomerase Reverse Transcriptase) • STRN (Striatin) • RAS (Rat Sarcoma Virus) • AGK (Acylglycerol Kinase) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • PAX8 (Paired box 8)

BRAF V600E • BRAF V600 • BRAF fusion • AGK-BRAF fusion • STRN-ALK fusion

over1year

Liquid Biopsy-based Umbrella Trial for Advanced NSCLC: Results of Phase 2 Plasma ALK-positive Cohort (A-Liquid) (IASLC-WCLC 2023)

Although precision medicine based on liquid NGS remains challenging due to the low PPA for fusion genes, alectinib is active in highly selected NSCLC populations with ALK rearrangement detected by both tissue-based assays and liquid NGS. Additional analysis on resistance mechanisms using paired blood samples will be presented.

over 1 year ago

P2 data • Liquid biopsy • Metastases • Biopsy

ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • EML4 (EMAP Like 4) • STRN (Striatin)

ALK positive • ALK rearrangement • ALK fusion • ROS1 fusion • ROS1 positive • STRN-ALK fusion • ALK-ROS1 fusion

Guardant360® CDx

Alecensa (alectinib)

over1year

Molecular genetics of diffuse sclerosing papillary thyroid cancer. (PubMed, J Clin Endocrinol Metab)

In DSPTC, fusion genes are common, BRAFV600E is rare, and other usual point mutations are absent. Pathogenic and likely pathogenic variants in POLE, NF1, CDKN2A, BRCA2, TP53, SETD2, ATM, FLT3 and ROS1 occur in about two-thirds of DTPTC.

over 1 year ago

Journal • BRCA Biomarker

KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • HRAS (Harvey rat sarcoma viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NF1 (Neurofibromin 1) • CCDC6 (Coiled-Coil Domain Containing 6) • STRN (Striatin) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • NCOA4 (Nuclear Receptor Coactivator 4)

TP53 mutation • BRAF V600E • PIK3CA mutation • PTEN mutation • ALK fusion • ALK mutation • STRN-ALK fusion

2years

Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer. (PubMed, Curr Oncol)

Recent clinical studies in the ALK-positive NSCLC population have demonstrated differences in progression-free survival (PFS) among patients based on different ALK fusion subtypes. This article will introduce the biological characteristics of ALK fusion kinase and common detection methods of ALK fusion and focus on summarizing the differential responses of several rare ALK fusions to ALK-TKIs, and propose corresponding treatment strategies, so as to better guide the application of ALK-TKIs in rare ALK fusion population.

2 years ago

Review • Journal • IO biomarker

ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4) • STRN (Striatin) • HIP1 (Huntingtin Interacting Protein 1)

ALK positive • ALK fusion • ALK mutation • STRN-ALK fusion

2years

DIFFUSE SCLEROSING PAPILLARY THYROID CANCER: PATHOLOGICAL FEATURES, MOLECULAR GENETICS AND OUTCOME (ATA 2022)

DSVPTC is an aggressive type of PTC affecting mostly young patients and is characterized by frequent lymph node and distant metastases. Fusion genes especially RET‐PTC1 are the most common genetic alterations. BRAF V600E and other usual somatic point mutations are rare to absent.

2 years ago

Late-breaking abstract • BRCA Biomarker

HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • HRAS (Harvey rat sarcoma viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NF1 (Neurofibromin 1) • TERT (Telomerase Reverse Transcriptase) • STRN (Striatin) • FGFR4 (Fibroblast growth factor receptor 4) • TSC2 (TSC complex subunit 2) • RAS (Rat Sarcoma Virus) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • NCOA4 (Nuclear Receptor Coactivator 4)

TP53 mutation • BRAF V600E • KRAS mutation • NRAS mutation • PIK3CA mutation • BRAF V600 • PTEN mutation • NF1 mutation • ALK fusion • HRAS mutation • FGFR4 mutation • TSC2 mutation • STRN-ALK fusion

Oncomine™ Comprehensive Assay v3M

2years

THE IN VITRO EFFECT OF ALK INHIBITORS IN STRN‐ALK ANAPLASTIC THYROID CANCER (ATA 2022)

This study permitted to evaluate in vitro the antineoplastic effect of crizotinib in human pATC (with STRN‐ALK), opening the way to future clinical evaluations in these patients.

2 years ago

Preclinical

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • HRAS (Harvey rat sarcoma viral oncogene homolog) • STRN (Striatin) • NCOA4 (Nuclear Receptor Coactivator 4) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • PAX8 (Paired box 8)

KRAS mutation • BRAF mutation • NRAS mutation • ALK positive • ALK rearrangement • ALK fusion • ALK mutation • HRAS mutation • STRN-ALK fusion

Xalkori (crizotinib)

almost3years

Acquired concurrent EGFR T790M and driver gene resistance from EGFR-TKIs hampered osimertinib efficacy in advanced lung adenocarcinoma (ELCC 2022)

One patient had acquired EGFR T790M, STRN-ALK fusion, and EGFR amplification after gefitinib progression and was shortly resistant to osimertinib with MET amplification. The other patient developed to acquired EGFR T790M and MET amplification post-dacomitinib and acquired CCDC6-RET fusion after 4-month osimertinib treatment...The T790M accompanying diver gene resistance will be a new subtype after EGFR-TKIs progression and needs effective treatment options. Legal entity responsible for the study The authors.

almost 3 years ago

Clinical

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • CCDC6 (Coiled-Coil Domain Containing 6) • STRN (Striatin)

EGFR mutation • HER-2 amplification • MET amplification • EGFR T790M • RET fusion • EGFR amplification • ALK fusion • CCDC6-RET fusion • KRAS G12 • KRAS amplification • STRN-ALK fusion • ALK amplification • EGFR T790M + HER-2 amplification • EGFR T790M + MET amplification

Tagrisso (osimertinib) • gefitinib • Vizimpro (dacomitinib)

almost3years

Clinical and molecular characterization of thyroid cancer when seen as a second malignant neoplasm. (PubMed, Ther Adv Endocrinol Metab)

Monitoring of cancer survivors for thyroid disorders allowed diagnosis of second thyroid cancers at early stages. Second thyroid cancers harbor genomic alterations that are typical for sporadic as well as for radio-induced thyroid cancers.

almost 3 years ago

Journal

BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • STRN (Striatin)

BRAF mutation • RET fusion • ALK fusion • RET mutation • STRN-ALK fusion

Oncomine Focus Assay

almost3years

Single cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib resistant patients. (PubMed, Ann Oncol)

Distinct molecular driver alterations at osimertinib resistance co-exist with initial EGFR mutations in single cancer cells. The clonal evolution of cancer cell populations emphasized their heterogeneity leading to osimertinib relapse. Combining two targeted treatments is effective to achieve clinical benefit.

almost 3 years ago

Journal

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • FGFR3 (Fibroblast growth factor receptor 3) • KIF5B (Kinesin Family Member 5B) • TACC3 (Transforming acidic coiled-coil containing protein 3) • STRN (Striatin)

KRAS mutation • EGFR mutation • BRAF mutation • ALK fusion • KIF5B-RET fusion • FGFR3 fusion • STRN-ALK fusion

Xalkori (crizotinib) • Tagrisso (osimertinib) • Alunbrig (brigatinib)

3years

Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review. (PubMed, J Cell Mol Med)

Both patients demonstrated improved survival after they switched to second-line crizotinib (PFS: 11 months) and ensartinib (PFS: 18 months), respectively, up till the last follow-up assessment. This study and literature review results showed mixed responses to alectinib in NSCLC patients who harboured rare ALK fusions. Comprehensive molecular profiling of tumour is thus strongly warranted for precise treatment strategies.

3 years ago

Clinical • Review • Journal

ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • STRN (Striatin)

ALK positive • MET amplification • ALK rearrangement • ALK fusion • STRN-ALK fusion

Xalkori (crizotinib) • Alecensa (alectinib) • Ensacove (ensartinib)

over3years

Coexistence of a secondary STRN-ALK, EML4-ALK double-fusion variant in a lung adenocarcinoma patient with EGFR mutation: a case report. (PubMed, Anticancer Drugs)

After 3 months of gefitinib treatment, an NGS of plasma circulating tumor DNA showed that all variants disappeared significantly, and the tumor mass regressed on CT. Moreover, a subsequent genotype by NGS also showed the disappearance of STRN-ALK and EGFR exon20 T790M. The therapeutic efficacy of crizotinib plus osimertinib on EML4-ALK and STRN-ALK double-fusion variant in patients with EGFR-resistant mutant lung cancer may provide a supportive reference for the patients with such genetic alteration.

over 3 years ago

Clinical • Journal

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • EML4 (EMAP Like 4) • RB1 (RB Transcriptional Corepressor 1) • STRN (Striatin)

TP53 mutation • EGFR mutation • EGFR L858R • ALK positive • EGFR T790M • EGFR exon 20 insertion • ALK rearrangement • EML4-ALK fusion • ALK fusion • EGFR exon 20 mutation • STRN-ALK fusion

Xalkori (crizotinib) • Tagrisso (osimertinib) • gefitinib

over3years

Identification of novel ALK fusions using DNA / RNA sequencing in immunohistochemistry / RT-PCR discordant NSCLC patients. (PubMed, Hum Pathol)

The discordance of IHC/RT-PCR was mainly due to limited coverage of non-EML4-ALK fusions in the RT-PCR assay. NGS based DNA/RNA sequencing appears to be a promising rescue technique for non-clear-cut IHC/RT-PCR cases and also offers a unique opportunity to identify novel ALK fusions.

over 3 years ago

Clinical • Journal

ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4) • STRN (Striatin) • DCTN1 (Dynactin Subunit 1) • CLTC (Clathrin Heavy Chain)

ALK rearrangement • EML4-ALK fusion • ALK fusion • STRN-ALK fusion • DCTN1-ALK fusion

over3years

[VIRTUAL] Incidence and heterogeneity of C797S and other EGFR resistance mutations on routine comprehensive genomic profiling (CGP). (ASCO 2021)

Funding: Foundation Medicine Background: The emergence of osimertinib (osi) as standard of care therapy for EGFR-mutant NSCLC has led to investigations into understanding and overcoming drug resistance... Osi resistance in EGFR-mutant NSCLC is a poor prognosis condition . EGFR C797S is a recurring resistance mut which, in a minority of cases, can co-occur with alternate on and off target resistance muts detected with tissue and liquid biopsy.

over 3 years ago

IO biomarker

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • RET (Ret Proto-Oncogene) • FGFR3 (Fibroblast growth factor receptor 3) • TACC3 (Transforming acidic coiled-coil containing protein 3) • CCDC6 (Coiled-Coil Domain Containing 6) • STRN (Striatin)

BRAF V600E • EGFR mutation • HER-2 amplification • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • RET fusion • FGFR3-TACC3 fusion • ALK fusion • EGFR C797S • CCDC6-RET fusion • EGFR S768I • BRAF fusion • EGFR G719A • FGFR3 fusion • STRN-ALK fusion • EGFR G724S • EGFR L718Q • EGFR G796S

Tagrisso (osimertinib)

almost4years

A novel malignant peritoneal mesothelioma with STRN exon 2 and ALK exon 20 : a case report and literature review. (PubMed, Oncologist)

The case did not respond to chemotherapy and is currently in a clinical trial of alectinib...ALK rearrangement and the fusion partner can be detected by companion diagnostics and by next generation sequencing. MPM patients with ALK rearrangement may benefit from target therapy.

almost 4 years ago

Clinical • Review • Journal

ALK (Anaplastic lymphoma kinase) • STRN (Striatin) • EWSR1 (EWS RNA Binding Protein 1) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor)

ALK rearrangement • ALK fusion • STRN-ALK fusion

Alecensa (alectinib)

almost4years

High STRN Expression Promotes HCC Invasion and Migration but Not Cell Proliferation or Apoptosis through Facilitating Epithelial-Mesenchymal Transition. (PubMed, Biomed Res Int)

Finally, STRN was further proved to be negatively related to E-cadherin expression but positively related to Vimentin expression in human HCC tissue samples. Taken together, STRN is upregulated in HCC and acts as a tumour promoter regulating cell invasion and migration through facilitating the EMT process.

almost 4 years ago

Journal

ALK (Anaplastic lymphoma kinase) • STRN (Striatin) • CDH1 (Cadherin 1) • VIM (Vimentin)

ALK fusion • STRN-ALK fusion • CDH1 expression • VIM expression

almost4years

Pediatric Mesothelioma With ALK Fusions: A Molecular and Pathologic Study of 5 Cases. (PubMed, Am J Surg Pathol)

In the remaining 2 cases, ALK gene rearrangements were demonstrated by fluorescence in situ hybridization. Unlike adult mesotheliomas, which are tightly linked to asbestos exposure, often show loss of BAP1 expression and have complex karyotypes, ALK-rearranged mesothelioma appears to be similar to other fusion-positive mesotheliomas, such as those harboring EWSR1/FUS-ATF1 fusions, sharing significant morphologic overlap, occurring in young patients and displaying a simple, translocation-driven genetic profile.

almost 4 years ago

Journal • Clinical

ALK (Anaplastic lymphoma kinase) • BAP1 (BRCA1 Associated Protein 1) • STRN (Striatin) • WT1 (WT1 Transcription Factor) • EWSR1 (EWS RNA Binding Protein 1) • FUS (FUS RNA Binding Protein) • ATF1 (Activating Transcription Factor 1) • PAX8 (Paired box 8)

ALK rearrangement • ALK fusion • STRN-ALK fusion

Archer® FusionPlex® Oncology Research Kit

4years

[VIRTUAL] Targeted Mutational Analysis of Predictive and Prognostic Biomarkers in Colorectal Carcinoma (AMP 2020)

Although many of the detected gene variants would have been identified by our previous and smaller 50 gene panel, the expanded TST170 panel detected 34 potentially clinically actionable variants including 2 fusions and copy number variants not detected by the smaller panel.

4 years ago

HER-2 amplification • ALK fusion • STRN-ALK fusion

4years

Colorectal Adenocarcinomas Harboring ALK Fusion Genes: A Clinicopathologic and Molecular Genetic Study of 12 Cases and Review of the Literature. (PubMed, Am J Surg Pathol)

Aberration of p53 signaling, TP53 mutations, and/or nuclear accumulation of p53 protein was seen in 9 cases. ALK fusion colorectal carcinomas are a distinct and rare subtype of colorectal cancers displaying some features of mismatch repair-deficient tumors.

4 years ago

Clinical • Review • Journal • PD(L)-1 Biomarker

PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • EML4 (EMAP Like 4) • STRN (Striatin) • CDX2 (Caudal Type Homeobox 2) • MUC2 (Mucin 2)

TP53 mutation • MSI-H/dMMR • BRAF mutation • ALK positive • PTEN mutation • ALK fusion • STRN-ALK fusion • TP53 mutation + ALK positive • TILs

4years

Detection of STRN-ALK fusion in thyroid nodules with indeterminate cytopathology facilitates papillary thyroid cancer diagnosis. (PubMed, Diagn Cytopathol)

This led to the patient undergoing a thyroid lobectomy and a subsequent confirmation of papillary thyroid carcinoma upon resection. The report highlights the role of comprehensive molecular testing in thyroid lesions of indeterminate cytology.

4 years ago

Journal

ALK (Anaplastic lymphoma kinase) • STRN (Striatin)

ALK fusion • STRN-ALK fusion

over4years

Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization. (PubMed, Mod Pathol)

Characteristic histology with multinodular growth and prominent fibrosis, particularly when there is extensive lymphovascular spread, should trigger molecular testing for gene rearrangements, either in a step-wise manner by prevalence or using a combined panel. Further, our findings provide information on molecular therapy in radioiodine-refractory thyroid carcinomas.

over 4 years ago

Clinical • Journal

EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • EML4 (EMAP Like 4) • JAK2 (Janus kinase 2) • GNAQ (G Protein Subunit Alpha Q) • CCDC6 (Coiled-Coil Domain Containing 6) • ETV6 (ETS Variant Transcription Factor 6) • PTCH1 (Patched 1) • STRN (Striatin) • GNA11 (G Protein Subunit Alpha 11) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • CDH1 (Cadherin 1) • TSC2 (TSC complex subunit 2) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • TPM3 (Tropomyosin 3) • NCOA4 (Nuclear Receptor Coactivator 4) • SQSTM1 (Sequestosome 1) • AGK (Acylglycerol Kinase) • AKT2 (V-akt murine thymoma viral oncogene homolog 2)

STRN-ALK fusion

over4years

Characterization of Thyroid Cancer Driven by Known and Novel ALK Fusions. (PubMed, Endocr Relat Cancer)

Compared to EML4-ALK, STRN-ALK may be more common in PDTC, and ~10% of ALK fusions occur to rare gene partners. When ALK fusion is detected preoperatively in FNA samples, malignancy should be expected.

over 4 years ago

Journal

ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4) • STRN (Striatin)

ALK fusion • ALK translocation • STRN-ALK fusion

over4years

Salivary Intraductal Carcinoma Arising within Intraparotid Lymph Node: A Report of 4 Cases with Identification of a Novel STRN-ALK Fusion. (PubMed, Head Neck Pathol)

Furthermore, identification of a STRN-ALK fusion expands the genetic spectrum of IDC and adds to evidence of an emerging role for ALK in salivary gland tumors. Further attention to the nature of the myoepithelial cells and documentation of alternate fusion events in IDC may inform continued discussion about its appropriate classification.

over 4 years ago

Clinical • Journal

ALK (Anaplastic lymphoma kinase) • STRN (Striatin) • NCOA4 (Nuclear Receptor Coactivator 4)

RET fusion • ALK fusion • NCOA4-RET fusion • STRN-ALK fusion

over4years

[VIRTUAL] Characterization of multiple driver alterations in acquired resistance to osimertinib in EGFR-mutated lung cancer: implementation of single cell approaches (AACR-II 2020)

Combining targeted therapies represents a valuable therapeutic opportunity to overcome drug resistance in EGFR-mutated lung cancer. Updated results will be presented at the Meeting.

over 4 years ago

Preclinical • IO biomarker

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • FGFR3 (Fibroblast growth factor receptor 3) • TACC3 (Transforming acidic coiled-coil containing protein 3) • STRN (Striatin)

BRAF V600E • EGFR mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • RET fusion • ALK fusion • FGFR3 mutation • FGFR3 fusion • STRN-ALK fusion • EGFR L858R + EGFR exon 19 deletion • IKZF1 deletion + PAX5 deletion

Tagrisso (osimertinib)

over4years

[VIRTUAL] Genomic characterization and outcome evaluation of kinome fusions in a large non-small cell lung cancer population. (ASCO 2020)

In addition, among patients with novel fusions, RORB-ALK and AFF2-RET may potentially function as oncogenic drivers in lung cancer and have demonstrated clinical benefit from crizotinib treatment. Our data have depicted a comprehensive overview of the landscape of kinase fusions in lung cancer, which helps recognize potentially druggable fusions and translate into therapeutic applications. Research Funding: None

over 4 years ago

Clinical

ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • FGFR3 (Fibroblast growth factor receptor 3) • EML4 (EMAP Like 4) • KIF5B (Kinesin Family Member 5B) • CD74 (CD74 Molecule) • TACC3 (Transforming acidic coiled-coil containing protein 3) • CCDC6 (Coiled-Coil Domain Containing 6) • STRN (Striatin) • SLC34A2 (Solute carrier family 34 member 2) • TPM3 (Tropomyosin 3) • CUX1 (cut like homeobox 1) • AFF2 (AF4/FMR2 family member 2)

NTRK1 fusion • ALK rearrangement • ALK fusion • ROS1 rearrangement • FGFR3 fusion • STRN-ALK fusion

Xalkori (crizotinib)